GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (FRA:9Y4) » Definitions » Additional Paid-In Capital

Ryvu Therapeutics (FRA:9Y4) Additional Paid-In Capital : €123.48 Mil(As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Ryvu Therapeutics Additional Paid-In Capital?


Ryvu Therapeutics's quarterly additional paid-in capital stayed the same from Sep. 2024 (€123.48 Mil) to Dec. 2024 (€123.48 Mil) and stayed the same from Dec. 2024 (€123.48 Mil) to Mar. 2025 (€123.48 Mil).

Ryvu Therapeutics's annual additional paid-in capital increased from Dec. 2022 (€66.30 Mil) to Dec. 2023 (€123.48 Mil) but then stayed the same from Dec. 2023 (€123.48 Mil) to Dec. 2024 (€123.48 Mil).

Ryvu Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Ryvu Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ryvu Therapeutics Additional Paid-In Capital Chart

Ryvu Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.30 66.30 66.30 123.48 123.48

Ryvu Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 123.48 123.48 123.48 123.48 123.48

Ryvu Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Ryvu Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Ryvu Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Ryvu Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (FRA:9Y4) » Definitions » Additional Paid-In Capital
Comparable Companies
WAR:BCX WAR:SVE WAR:BIO WAR:MOC WAR:PTG WAR:CTX WAR:MAB WAR:URT WAR:NNG WAR:RDG VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
RVU:Poland 9Y4:Germany
Address
Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Website
https://www.ryvu.com
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics Headlines

No Headlines